cellceutix - Home

cellceutix is an emerging bio-pharmaceutical company
focusing in the areas of cancer
and inflammatory disease...

Kevetrin™ - success in animal models

Companies such as Cellceutix are doing research in lung cancer due to the high incidence of lung cancer and poor survival rates, which create a high level of medical need. We at Cellceutix recently announced some very promising results of a series of animal tests of our lead compound, Kevetrin™, in two multi-drug resistant lung cancer cell lines (A549 & NCI-H1975).

American Association for Cancer Research (AACR) Debuts Frontiers in Basic Cancer Research Meeting

"Scientists at Cellceutix Corporation may have developed a new compound that could significantly delay lung tumor growth, according to data presented at the AACR Frontiers in Basic Cancer Research Meeting."

full article: http://www.aacr.org/home/public--media/aacr-press-releases.aspx?d=1584

Download Cellceutix Poster presented at AACR

Kevetrin^TM Demonstrates Significant Delay of Tumor Growth in Drug Resistant Breast Cancer

Kevetrin^TM Animal Model Testing Success Against Multi-Drug Resistant Lung Cancer

Cellceutix Compund KM-133 Shows Significant Effect On Psoriasis

From the desk of our CEO, George W. Evans, JD, MBA

In my last letter I talked about changing directions. It's not unexpected in our business and is often a natural result of learning more about our products--that's what gets us up in the morning. Our recent progress has been a bit more linear, though, and we've found with Kevetrin(TM) that the more we learn, the more interesting it gets.

Over the past few months, we've done both in vitro and in vivo studies as we prepare for our IND filing with the U.S. FDA. With each study we've become more encouraged about the prospects for Kevetrin. We've found that the first results in drug resistant lung cancer cell lines weren't a fluke--in fact we've found consistently good activity in drug resistant breast cancer cell lines, as well. And we've started to learn that Kevetrin is pretty selective in the way it impacts anti-tumor pathways. It's not primarily a cytotoxic compound, with all the baggage that can bring.

Full Letter....